日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

SGLT2 抑制可通过促进酮体诱导的 mTORC1 抑制来介导对糖尿病肾病的保护

Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda-Yamahara, Naoko Takeda, Masami Chin-Kanasaki, Tatsuroh Kaneko, Eric Mayoux, Michael Mark, Motoko Yanagita, Hisakazu Ogita, Shin-Ichi Araki, Hiroshi Maegawa

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

恩格列净改善代谢综合征 ZSF1 大鼠的收缩压、内皮功能障碍和心脏重塑

Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel, Valérie B Schini-Kerth

Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence

血管紧张素 II 诱导的氧化还原敏感 SGLT1 和 2 表达促进高糖诱导的内皮细胞衰老

Sonia Khemais-Benkhiat, Eugenia Belcastro, Noureddine Idris-Khodja, Sin-Hee Park, Lamia Amoura, Malak Abbas, Cyril Auger, Laurence Kessler, Eric Mayoux, Florence Toti, Valérie B Schini-Kerth

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

SGLT2 抑制剂恩格列净控制血糖可降低主动脉僵硬程度、肾阻力指数和肾损伤

Annayya R Aroor, Nitin A Das, Andrea J Carpenter, Javad Habibi, Guanghong Jia, Francisco I Ramirez-Perez, Luis Martinez-Lemus, Camila M Manrique-Acevedo, Melvin R Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar, Vincent G DeMarco

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

恩格列净可增加糖尿病患者的心脏能量产生:SGLT2 抑制剂对心力衰竭益处的全新转化见解

Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux, Michael Lehrke, Nikolaus Marx, Gary D Lopaschuk

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

SGLT2 抑制剂恩格列净改善 ZDF 大鼠原发性糖尿病并发症

Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J Lackner, Leszek Wojnowski, Serge P Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel, Andreas Daibe

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

使用恩格列净抑制钠葡萄糖转运蛋白 2 (SGLT2) 可改善雌性糖尿病啮齿动物模型的心脏舒张功能

Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Brady Barron, Eric Mayoux, R Scott Rector, Adam Whaley-Connell, Vincent G DeMarco

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

SGLT2 抑制剂恩格列净对 1 型糖尿病患者胰腺 β 细胞质量和血糖稳态的影响

Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia

SGLT1 介导的转运增加解释了在正常血糖条件下遗传和药理学 SGLT2 抑制期间肾脏葡萄糖重吸收的情况

Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净通过干扰氧化应激和糖毒性改善链脲佐菌素糖尿病大鼠模型中糖尿病引起的血管功能障碍

Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova, Anna Gottschlich, Sebastian Steven, Eberhard Schulz, Serge P Bottari, Eric Mayoux, Thomas Münzel, Andreas Daiber